Therapeutic Asset Ratings
9,928 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
exs73565
Diffuse Large B-Cell Lymphoma
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
CC
(43)
exs73565
Marginal Zone Lymphoma
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
CC
(43)
exs73565
Waldenstrom Macroglobulinemia
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
CC
(43)
exs74539
Head And Neck Squamous Cell Carcinoma
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
CC
(43)
exs74539
Liver Cancer
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
CC
(43)
exs74539
Neuroendocrine Carcinoma
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
CC
(43)
Ex-Vivo Expanded Autologous Il-8 Receptor Modified Cd70 Car T Cells
Malignant Glioma
University of Florida
P1
CC
(43)
Ezabenlimab
Neuroendocrine Neoplasm
Boehringer Ingelheim
P1
CC
(43)
Ezabenlimab
Small Cell Lung Carcinoma
Boehringer Ingelheim
P1
CC
(43)
Ezabenlimab
Colon Adenocarcinoma
Amal Therapeutics
P1
CC
(43)
Ezabenlimab
Rectal Carcinoma
Amal Therapeutics
P1
CC
(43)
ezm0414
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Epizyme, Inc.
P1
CC
(43)
ezm0414
Plasma Cell Myeloma
Epizyme, Inc.
P1
CC
(43)
f527
Lymphoma
Shandong New Time Pharmaceutical Co., LTD
P1
CC
(43)
Falimarev
Pancreatic Acinar Cell Carcinoma
National Cancer Institute (NCI)
P1
CC
(43)
Falimarev
Malignant Pancreatic Neoplasm
National Cancer Institute (NCI)
P1
CC
(43)
Fam-Trastuzumab Deruxtecan-Nxki
Estrogen-Receptor Positive Breast Cancer
QuantumLeap Healthcare Collaborative
P1
CC
(43)
Fam-Trastuzumab Deruxtecan-Nxki
Non-Small Cell Lung Carcinoma
Enliven Therapeutics
P1
CC
(43)
Fam-Trastuzumab Deruxtecan-Nxki
Neoplasm
QuantumLeap Healthcare Collaborative
P1
CC
(43)
Fam-Trastuzumab Deruxtecan-Nxki
Breast Carcinoma
QuantumLeap Healthcare Collaborative
P1
CC
(43)
Fam-Trastuzumab Deruxtecan-Nxki
Hormone Receptor-Positive Breast Cancer
QuantumLeap Healthcare Collaborative
P1
CC
(43)
Fam-Trastuzumab Deruxtecan-Nxki
Metastatic Neoplasm
QuantumLeap Healthcare Collaborative
P1
CC
(43)
Fam-Trastuzumab Deruxtecan-Nxki
Progesterone-Receptor Positive Breast Cancer
QuantumLeap Healthcare Collaborative
P1
CC
(43)
Fapi-46
Bile Duct Neoplasm
Karolinska University Hospital
P1
CC
(43)
Fapi-46
Urinary Bladder Carcinoma
Jonsson Comprehensive Cancer Center
P1
CC
(43)
Showing 2026 to 2050 of 9,928 assets
Previous
Page 82 of 398
Next
